Your browser is no longer supported. Please, upgrade your browser.
ARCA biopharma, Inc.
Index- P/E- EPS (ttm)-1.54 Insider Own0.40% Shs Outstand14.41M Perf Week2.95%
Market Cap40.76M Forward P/E- EPS next Y- Insider Trans52.03% Shs Float14.35M Perf Month-8.52%
Income-16.10M PEG- EPS next Q- Inst Own8.30% Short Float2.21% Perf Quarter-3.13%
Sales- P/S- EPS this Y50.20% Inst Trans- Short Ratio1.30 Perf Half Y-17.70%
Book/sh4.25 P/B0.66 EPS next Y- ROA-27.10% Target Price- Perf Year-34.97%
Cash/sh4.33 P/C0.64 EPS next 5Y- ROE-28.60% 52W Range2.65 - 5.50 Perf YTD-30.42%
Dividend- P/FCF- EPS past 5Y42.50% ROI- 52W High-49.27% Beta2.59
Dividend %- Quick Ratio17.50 Sales past 5Y- Gross Margin- 52W Low5.28% ATR0.11
Employees11 Current Ratio17.50 Sales Q/Q- Oper. Margin- RSI (14)43.03 Volatility3.67% 3.70%
OptionableYes Debt/Eq0.00 EPS Q/Q53.80% Profit Margin- Rel Volume0.32 Prev Close2.83
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout- Avg Volume244.81K Price2.79
Recom- SMA20-3.45% SMA50-5.84% SMA200-22.40% Volume77,754 Change-1.41%
Feb-27-18Initiated Ascendiant Capital Markets Buy $2
Oct-09-13Initiated Dawson James Buy $3.75
Sep-16-21 08:30AM  
Aug-16-21 08:05AM  
Aug-12-21 01:15AM  
Aug-09-21 08:00AM  
Aug-04-21 04:15PM  
Jul-28-21 08:00AM  
Jul-13-21 08:00AM  
Jul-09-21 08:00AM  
Jul-08-21 11:20AM  
Jul-07-21 08:00AM  
Jun-23-21 09:35AM  
May-11-21 04:15PM  
May-05-21 04:05PM  
May-03-21 04:30PM  
Mar-18-21 04:30PM  
Feb-13-21 01:09AM  
Dec-15-20 08:30AM  
Dec-09-20 05:40PM  
Nov-23-20 12:28PM  
Nov-02-20 08:30AM  
Oct-07-20 08:30AM  
Oct-05-20 04:30PM  
Sep-21-20 08:00AM  
Aug-17-20 08:49AM  
Aug-12-20 08:00AM  
Aug-05-20 04:15PM  
Jul-07-20 08:30AM  
Jun-03-20 09:56AM  
Jun-01-20 08:20AM  
May-29-20 12:24PM  
May-28-20 04:19PM  
May-07-20 08:30AM  
May-06-20 04:30PM  
Feb-18-20 04:30PM  
Feb-01-20 08:31AM  
Nov-06-19 04:10PM  
Nov-03-19 08:47AM  
Sep-12-19 08:30AM  
Sep-11-19 08:30AM  
Sep-04-19 01:37PM  
Aug-21-19 09:49AM  
Aug-01-19 04:30PM  
Jun-04-19 07:09AM  
May-13-19 09:00AM  
May-08-19 04:30PM  
May-01-19 08:30AM  
Apr-23-19 08:30AM  
Mar-18-19 08:30AM  
Mar-06-19 08:00AM  
Feb-27-19 04:15PM  
Feb-20-19 07:30AM  
Jan-16-19 08:30AM  
Dec-26-18 11:47AM  
Dec-20-18 04:01PM  
Nov-14-18 04:30PM  
Nov-12-18 08:30AM  
Nov-05-18 08:30AM  
Oct-10-18 04:16PM  
Oct-02-18 08:00AM  
Sep-18-18 08:30AM  
Aug-09-18 04:15PM  
Aug-03-18 09:45AM  
Jul-31-18 12:15PM  
Jun-19-18 07:05AM  
May-29-18 08:30AM  
May-11-18 08:20AM  
May-10-18 08:30AM  
May-08-18 04:15PM  
Apr-23-18 08:30AM  
Apr-03-18 07:20AM  
Mar-22-18 04:30PM  
Feb-27-18 03:00PM  
Feb-26-18 02:18PM  
Jan-23-18 05:13PM  
Jan-08-18 08:30AM  
Jan-02-18 05:09PM  
Dec-08-17 06:13PM  
Nov-30-17 02:25PM  
Nov-20-17 08:05AM  
Nov-17-17 08:10AM  
Nov-16-17 08:30AM  
Nov-09-17 04:05PM  
Oct-23-17 08:16PM  
Sep-21-17 08:30AM  
Aug-16-17 08:30AM  
Aug-09-17 04:30PM  
Aug-03-17 04:15PM  
Jun-20-17 08:30AM  
May-15-17 08:30AM  
Apr-26-17 08:30AM  
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CONWAY ROBERT EChairman of the BoardMay 12Buy3.1910,00031,94750,000May 13 05:00 PM
CONWAY ROBERT EChairman of the BoardMay 05Buy3.2310,00032,34540,000May 06 04:30 PM
CONWAY ROBERT EChairman of the BoardDec 18Buy4.1610,00041,63030,000Dec 21 04:15 PM
ALPN Alpine Immune Sciences, Inc. daily Stock Chart
Alpine Immune Sciences, Inc.
Index- P/E- EPS (ttm)-1.49 Insider Own1.40% Shs Outstand23.91M Perf Week-4.29%
Market Cap279.95M Forward P/E- EPS next Y-1.53 Insider Trans- Shs Float16.16M Perf Month14.37%
Income-34.20M PEG- EPS next Q-0.09 Inst Own61.90% Short Float2.93% Perf Quarter34.36%
Sales18.00M P/S15.55 EPS this Y41.20% Inst Trans11.66% Short Ratio5.57 Perf Half Y3.83%
Book/sh1.83 P/B6.22 EPS next Y-6.90% ROA-23.20% Target Price20.00 Perf Year29.91%
Cash/sh3.70 P/C3.08 EPS next 5Y- ROE-60.20% 52W Range7.21 - 16.37 Perf YTD-9.68%
Dividend- P/FCF- EPS past 5Y-12.60% ROI-39.80% 52W High-30.48% Beta1.51
Dividend %- Quick Ratio2.30 Sales past 5Y80.10% Gross Margin- 52W Low57.84% ATR0.76
Employees57 Current Ratio2.30 Sales Q/Q928.60% Oper. Margin- RSI (14)55.63 Volatility5.82% 7.47%
OptionableYes Debt/Eq0.24 EPS Q/Q13.60% Profit Margin- Rel Volume0.37 Prev Close11.49
ShortableYes LT Debt/Eq0.13 EarningsAug 10 AMC Payout- Avg Volume85.06K Price11.38
Recom1.60 SMA202.09% SMA5013.98% SMA2004.50% Volume31,512 Change-0.96%
Dec-21-20Initiated H.C. Wainwright Buy $21
Aug-26-20Initiated Cowen Outperform
Oct-02-21 08:06AM  
Sep-28-21 09:42AM  
Sep-24-21 10:29AM  
Sep-22-21 12:04PM  
Sep-15-21 08:05AM  
Sep-07-21 04:05PM  
Aug-18-21 06:04AM  
Aug-10-21 05:45PM  
Aug-04-21 08:00AM  
Aug-03-21 03:00PM  
Jul-30-21 09:55AM  
Jul-24-21 03:25AM  
Jul-01-21 10:51AM  
Jun-30-21 08:00AM  
Jun-24-21 08:00AM  
Jun-13-21 05:28AM  
Jun-08-21 08:00AM  
Jun-04-21 04:05PM  
Jun-03-21 08:14AM  
Jun-02-21 04:05PM  
May-23-21 06:43AM  
May-20-21 04:47AM  
May-19-21 05:10PM  
May-18-21 04:05PM  
May-13-21 06:45PM  
May-06-21 03:00PM  
May-05-21 01:41AM  
Apr-28-21 04:05PM  
Apr-16-21 08:28AM  
Apr-12-21 08:00AM  
Mar-21-21 03:30AM  
Mar-19-21 12:00AM  
Mar-18-21 05:35PM  
Mar-11-21 04:05PM  
Mar-10-21 04:30PM  
Feb-22-21 04:05PM  
Feb-03-21 11:36PM  
Jan-06-21 08:00AM  
Jan-01-21 07:04AM  
Dec-21-20 10:07AM  
Dec-20-20 11:29PM  
Dec-17-20 08:00AM  
Dec-11-20 10:23PM  
Dec-08-20 08:35AM  
Nov-24-20 04:05PM  
Nov-16-20 04:05PM  
Nov-15-20 07:03AM  
Nov-12-20 04:05PM  
Nov-05-20 04:05PM  
Oct-28-20 06:32AM  
Sep-15-20 04:05PM  
Sep-08-20 04:05PM  
Aug-26-20 09:42AM  
Aug-11-20 04:05PM  
Aug-05-20 04:05PM  
Aug-04-20 04:05PM  
Jul-24-20 09:15AM  
Jul-22-20 06:45AM  
Jul-08-20 09:05AM  
Jun-25-20 12:09PM  
Jun-24-20 08:00AM  
Jun-19-20 11:27AM  
Jun-18-20 10:22AM  
Jun-15-20 08:00AM  
Jun-11-20 06:57AM  
Jun-10-20 03:44PM  
Jun-08-20 08:00AM  
Jun-04-20 08:00AM  
May-29-20 08:00AM  
May-26-20 04:05PM  
May-16-20 08:11AM  
May-14-20 04:01PM  
Apr-27-20 09:00AM  
Apr-20-20 04:05PM  
Apr-13-20 06:15AM  
Apr-07-20 07:06AM  
Mar-30-20 04:01PM  
Mar-18-20 07:15AM  
Mar-02-20 04:05PM  
Feb-25-20 04:02PM  
Jan-24-20 07:30AM  
Jan-14-20 06:17AM  
Jan-06-20 07:30AM  
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CONWAY ROBERT EDirectorSep 21Buy9.8010,00097,96635,000Sep 23 08:31 PM
Cui XiangminDirectorSep 17Buy9.401,542,55314,499,9984,708,288Sep 21 05:12 PM
ORBIMED ADVISORS LLCDirectorSep 17Buy9.401,010,6379,499,9883,656,061Sep 21 06:42 PM
Decheng Capital China Life Sci10% OwnerSep 17Buy9.401,542,55314,499,9984,708,288Sep 21 06:39 PM
Thompson Peter A.DirectorSep 17Buy9.401,010,6379,499,9883,656,061Sep 21 06:38 PM
Alpine ImmunoSciences, L.P.10% OwnerSep 17Sale9.40400,0003,760,0002,600,980Sep 21 05:18 PM
GOLD MITCHELLExecutive Chairman and CEOSep 17Sale9.40400,0003,760,0002,600,980Sep 21 05:16 PM
GOLD MITCHELLExecutive Chairman and CEOSep 17Sale10.0145,262452,964109,387Sep 21 05:16 PM
Venkatesan JayDirectorSep 17Sale9.40400,0003,760,0002,600,980Sep 21 05:14 PM
GOLD MITCHELLExecutive Chairman and CEOSep 16Sale10.006,76867,696154,649Sep 17 06:06 PM
GOLD MITCHELLExecutive Chairman and CEOSep 15Sale10.003,48434,840161,417Sep 17 06:06 PM
GOLD MITCHELLExecutive Chairman and CEOJun 28Sale10.003,47934,792164,901Jun 29 05:13 PM
GOLD MITCHELLExecutive Chairman and CEOJun 25Sale10.019,47394,865168,380Jun 29 05:13 PM
GOLD MITCHELLExecutive Chairman and CEOMay 20Sale15.001,22118,316177,853May 21 05:16 PM
GOLD MITCHELLExecutive Chairman and CEOMay 19Sale15.0350,965765,917179,074May 21 05:16 PM
GOLD MITCHELLExecutive Chairman and CEOMay 13Sale11.5210,000115,169230,039May 14 05:17 PM
GOLD MITCHELLExecutive Chairman and CEOMay 12Sale11.6810,000116,842240,039May 14 05:17 PM
GOLD MITCHELLExecutive Chairman and CEOApr 14Sale10.5210,000105,200250,039Apr 15 06:09 PM
GOLD MITCHELLExecutive Chairman and CEOApr 13Sale10.0710,000100,714260,039Apr 15 06:09 PM
Venkatesan JayDirectorMar 31Option Exercise3.627,65027,718218,063Apr 23 06:14 PM
Venkatesan JayDirectorMar 30Option Exercise4.097,65031,288210,413Apr 23 06:14 PM
GOLD MITCHELLExecutive Chairman and CEOMar 05Sale12.9910,000129,875270,039Mar 08 05:01 PM
GOLD MITCHELLExecutive Chairman and CEOMar 04Sale13.0110,000130,108280,039Mar 08 05:01 PM
GOLD MITCHELLExecutive Chairman and CEOFeb 02Sale11.7410,000117,381290,039Feb 03 05:01 PM
GOLD MITCHELLExecutive Chairman and CEOFeb 01Sale12.8710,000128,665300,039Feb 03 05:01 PM
ORBIMED ADVISORS LLCDirectorDec 28Sale14.25600,0008,550,0003,070,955Dec 30 04:44 PM
Thompson Peter A.DirectorDec 28Sale14.25600,0008,550,0003,070,955Dec 30 04:38 PM
CONWAY ROBERT EDirectorNov 19Buy8.0310,00080,30025,000Nov 23 05:00 PM